| |
| |
|
| Insider
Information: |
Clackson Timothy P |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
737,796 |
|
|
Indirect Shares
|
118,218 |
|
|
| Direct
Value |
$359,460 |
|
|
|
Indirect Value
|
$167,548 |
|
|
| Total
Shares |
856,014 |
|
|
| Total
Value |
$527,009 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ariad Pharmaceuticals Inc |
ARIA |
President, R&D, CSO |
2016-03-22 |
316,212 |
2004-01-05 |
0 |
Premium* |
|
|
F-star Therapeutics, Inc |
FSTX |
Director |
2020-09-30 |
50,486 |
2018-07-02 |
0 |
Premium* |
|
|
Forma Therapeutics Holdings, Inc., |
FMTX |
Director |
2022-10-14 |
0 |
|
0 |
Premium* |
|
|
Theseus Pharmaceuticals, Inc. |
THRX |
President and CEO, Dir... |
2022-11-11 |
351,030 |
|
0 |
Premium* |
|
|
Xilio Therapeutics, Inc. |
XLO |
10% Owner |
2021-10-21 |
20,068 |
2021-10-21 |
70,888 |
Premium* |
|
|
Elevation Oncology, Inc. |
ELEV |
|
2023-09-01 |
0 |
2023-09-01 |
47,330 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
94 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FMTX |
Forma Therapeutics Holdin... |
Director |
– • – |
2020-06-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,572 |
|
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
President and CEOOfficer |
• • – |
2021-10-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
345,930 |
|
- |
|
| XLO |
Xilio Therapeutics, Inc. |
10% Owner |
– – • |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
70,888 |
|
- |
|
| XLO |
Xilio Therapeutics, Inc. |
10% Owner |
– – • |
2021-10-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,068 |
|
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
744 |
744 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2018-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
788 |
1,532 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,083 |
2,615 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
1,204 |
3,819 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Chief Scientific Officer |
• – – |
2006-03-10 |
4 |
OE |
$3.69 |
$5,397 |
D/D |
1,300 |
70,429 |
|
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
President and CEO |
• • – |
2022-11-11 |
4 |
B |
$6.80 |
$16,995 |
D/D |
2,500 |
351,030 |
2.81 |
- |
|
| THRX |
Theseus Pharmaceuticals, ... |
President and CEO |
• • – |
2021-12-21 |
4 |
B |
$9.76 |
$25,381 |
D/D |
2,600 |
348,530 |
2.81 |
- |
|
| FMTX |
Forma Therapeutics Holdin... |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
26,340 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,421 |
7,240 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2014-03-19 |
4 |
D |
$8.19 |
$28,190 |
D/D |
(3,442) |
387,711 |
0 |
- |
|
| FSTX |
F-star Therapeutics, Inc |
Director |
– • – |
2019-09-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,670 |
10,910 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2014-07-15 |
4 |
D |
$5.57 |
$25,421 |
D/D |
(4,564) |
413,565 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2012-04-03 |
4 |
AS |
$16.18 |
$84,134 |
D/D |
(5,200) |
272,489 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2015-03-20 |
4 |
AS |
$8.84 |
$47,910 |
D/D |
(5,417) |
433,648 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• – – |
2016-03-19 |
4 |
AS |
$6.47 |
$35,039 |
D/D |
(5,417) |
340,046 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SrVP, Chief Scientific Officer |
• – – |
2007-07-11 |
4 |
OE |
$4.31 |
$29,103 |
D/D |
6,400 |
76,829 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$117,245 |
D/D |
(6,500) |
363,705 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2014-04-02 |
4 |
AS |
$8.21 |
$53,337 |
D/D |
(6,500) |
403,028 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$129,718 |
D/D |
(6,667) |
338,039 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2014-03-21 |
4 |
AS |
$7.89 |
$52,583 |
D/D |
(6,667) |
394,377 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
President, R&D, CSO |
• • – |
2015-03-23 |
4 |
AS |
$8.55 |
$57,016 |
D/D |
(6,667) |
440,314 |
0 |
- |
|
94 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
